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Merkel cell carcinoma (MCC) is a rare cutaneous
malignancy with a high propensity for regional lymph
node metastasis and recurrence. Acute febrile neutrophilic
dermatosis (Sweet syndrome) is an acute inﬂammatory
skin eruption that is commonly associated with hemato-
logic malignancies, but cases in association with solid
tumors have also been reported.1 We present the ﬁrst case
of a 49-year-old female who experienced an acute ﬂare
up of Sweet syndrome during her initial diagnosis and
subsequent treatment for MCC.Case report
A 49-year-old Caucasian female presented with bilat-
eral erythematous patches and edematous plaques on the
cheek in June 2012. She had been experiencing the
eruption for more than 19 years. Previous skin biopsies,
as well as the skin biopsy of the cheek performed at the
time of consultation, demonstrated a diffuse, bandlike
inﬁltrate of neutrophils in the dermis consistent with
diagnosis of Sweet syndrome (Fig 1A, B and Fig 2). She
was started on a regimen of topical steroids in addition toConﬂicts of interest: None.
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sequent lesions were also transiently responsive to intra-
lesional triamcinolone injections, but typically failed to
respond to colchicine and nonsteroidal anti-inﬂammatory
drugs.
One month later, the patient presented with a new
nodule on her left cheek. Skin biopsy demonstrated
neoplastic cells displaying basaloid morphologic features
with vesicular nuclei, minimal cytoplasm, and indistinct
nucleoli suggestive of neuroendocrine carcinoma.
Immunohistochemistry was positive for cytokeratin 20
and negative for S-100 protein, CD-45, cytokeratin 7, and
transcription factor-1 within the neoplastic cells. Based on
these results, the patient was diagnosed with MCC
occurring in a background of chronic Sweet syndrome; to
our knowledge, this is the ﬁrst concurrence of these
disorders reported in the medical literature (Fig 3).
After review in multidisciplinary tumor board, patient
underwent wide local excision and sentinel lymph node
biopsy from the left parotid and left cervical nodal basin,
which was negative for metastatic disease. She was staged
as T1 N0 M0, stage IA, with subsequent positron emis-
sion tomography scans demonstrating no scintigraphic
evidence of residual or recurrent disease. She then
received 50 Gy external beam radiation using electrons at
2 Gy per fraction over 5 weeks to the primary site only
(Fig 4), without radiation to the lymphatic tissue, based on
multidisciplinary consensus from 2 different academic
institutions. The patient completed radiation treatments
2 months after initial diagnosis and tolerated the treatment
well. She experienced expected side effects includingof the American Society for Radiation Oncology. This is an open access
by-nc-nd/4.0/).
Figure 1 Bilateral erythematous patches and edematous plaques consistent with clinical diagnosis of Sweet syndrome before treat-
ment. (A, B) Photographs taken at time of computed tomography simulation with scar wire and head mask. (C) One month post-
treatment. (D) Six months posttreatment.
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desquamation of the irradiated ﬁeld (acute toxicity was
grade 2, which resolved within 4 weeks after completion
of radiation therapy). Restaging positron emission to-
mography and clinical examination 2 months out from
treatment completion showed no evidence of MCC, and
she was declared to be in complete remission. She has
followed up regularly and has not experienced any
recurrence of MCC (Fig 1C, D). The patient initially had a
dramatic improvement in her Sweet syndrome lesions,
which were located in the irradiated ﬁeld, during the
treatment course. She then had recurrence of Sweet syn-
drome with 2 lesions within the irradiated ﬁeld at 7 weeks
after radiation therapy, which responded to topical ther-
apy. She is currently well-managed with dapsone 100 mg
daily and topical clobetasol for both symptomatic andFigure 2 Punch biopsy of lesional skin at (A) 100 and (B) 200 d
neutrophils within the superﬁcial dermis with associated papillary derclinical control of her cutaneous lesions. The patient is
also on intermittent prednisone 40 mg tapers during acute
exacerbations of symptoms.Discussion
MCC is a rare cutaneous malignancy that typically
presents as a rapidly growing, nonpainful, ﬂesh-colored or
bluish-red, dermal nodule or cystic lesion. Initial clinical
impression is often that of benign lesions, which can
result in signiﬁcant delays in biopsy and diagnosis.
Treatment for MCC with a negative lymph node biopsy
involves surgical excision with either postoperative radi-
ation therapy or observation of the primary site. For MCC
with biopsy-positive nodes, a multidisciplinary tumoremonstrating a diffuse, bandlike inﬁltrate composed primarily of
mal edema consistent with Sweet syndrome.
Figure 3 Merkel cell carcinoma skin biopsy demonstrating nodules and sheets of basophilic tumor cells in the dermis and superﬁcial
subcutis at (A) 20 magniﬁcation and (B) 40 magniﬁcation. (C) 400 magniﬁcation demonstrating vesicular nuclei with small
nucleoli and scant cytoplasm. (D) Immunohistochemistry for cytokeratin 20 is positive in tumor cells seen at 400 magniﬁcation.
124 A. Liao et al Advances in Radiation Oncology: AprileJune 2016board treatment plan should be considered involving a
combination of lymph node dissection, radiation therapy,
or adjuvant chemotherapy. Adjuvant radiation therapy toFigure 4 Patient was simulated in the supine position with arms d
zation. The planning treatment volume (PTV) was deﬁned as the surg
used an internal eye shield to reduce dosage to critical eye structures. T
technique 44 Gy at 2 Gy per fraction, prescribed to the 90% isodose us
per fraction without bolus was boost was given for a total dose of 50
scribed radiation treatment was completed. (A) Axial view. (B) Coroprimary site is generally recommended for all excision
sites, despite mixed opinions about its beneﬁts. National
Comprehensive Cancer Network guidelines suggest aown, using a customized thermoplastic facemask for immobili-
ical scar plus a customized 3-cm margin, 2 cm near the eye. We
he left cheek PTV was treated using a 9 MeV electrons, en face
ing a 0.5-cm tissue equivalent bolus. An additional 6 Gy of 2 Gy
Gy. Heterogeneity correction was used for planning. The pre-
nal view. (C) Sagittal. (D) 3-dimensional rendering.
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tion margins, 56 to 60 Gy for microscopic resection
margins, and 60 to 66 Gy for gross or unresectable mar-
gins.2 Harrington and Kwan showed 5 year overall sur-
vival rates of 57%, 68%, and 39% for stage I, II, and III
disease, respectively, using deﬁnitive radiation therapy on
primary and/or nodal disease.3 We have typically offered
adjuvant radiation therapy to the primary in almost all
cases given our own clinical experience with observation
resulting in increased local recurrence.
Sweet syndrome is an inﬂammatory skin condition
characterized by tender, erythematous, edematous skin
lesions often affecting the head and neck.1 The disease
predominantly affects women and classically arises
between the ages of 30 to 60 years of age.4 There are 3
subtypes of Sweet syndrome. Classical Sweet syndrome is
induced by inﬂammatory conditions such as infections and
autoimmune disorders. Drug-induced Sweet syndrome
also represents a signiﬁcant portion of cases; a common
culprit is granulocyte colony stimulating factor. Finally,
malignancy-induced Sweet syndrome accounts for 10% to
20% of cases overall.1 The skin condition is predomi-
nately associated with hematological cancers (42% had
acute myelogenous leukemia)5,6; solid tumors are
less likely to be associated with Sweet syndrome. Topical
and systemic corticosteroids are the cornerstone of
management for Sweet syndrome.5 Nonsteroidal anti-
inﬂammatory drugs such as colchicine, potassium iodide,
and dapsone have also been reported as efﬁcacious.
There have been reports of Sweet syndrome arising
in association with other cutaneous malignancies,
including melanoma.7 However, our case is the ﬁrst
reported association of Sweet syndrome with MCC
reported in the medical literature. Our patient’s pre-
sentation is unique for several reasons. First, she was
diagnosed with the malignancy at a very young age;
MCC usually occurs in older males with a history of
extensive sun exposure.4 Second, MCC is a highly
immunogenic condition that is associated with other
malignancies and an immunosuppressed state. The pa-
tient had no other pertinent medical history beyond a
diagnosis of Sweet syndrome, and there were no med-
ical conditions that would have increased her risk for
MCC. Her relatively young age and lack of comorbid-
ities may account for her good prognosis because MCC
is traditionally an extremely aggressive disease with a
5-year disease-speciﬁc survival rate of 64% and a me-
dian overall survival duration of only 31 months.4,8
The manifestation of Sweet syndrome in this patient is
also unique given the relative lack of knowledge
regarding the pathophysiology of the disease. Specif-
ically, the treatment of our patient’s MCC did not involve
any use of chemotherapy, thus ruling out drug-induced
Sweet syndrome. In addition, she did not have any prior
infections or autoimmune conditions that would meet
criteria for classical Sweet syndrome. Although it isknown that nearly two-thirds of malignancy associated
Sweet syndrome patients develop the syndrome before or
concurrently with the diagnosis of the malignancy,1 the
diagnosis of Sweet syndrome in the patient occurred years
before the diagnosis of MCC. Thus, any causal relation-
ship between Sweet syndrome and MCC cannot be
demonstrated. However, it is possible that the immuno-
genic changes caused by the cancer further disrupted
autoinﬂammatory regulation in an already susceptible
patient, the results of which manifested as an acute ﬂare
up of Sweet syndrome in the month before the diagnosis
of MCC.
Finally, radiation therapy has been associated with
many dermatologic side effects, the most common of
which include benign dermatoses such as bullous pem-
phigoid, pemphigus vulgaris, and morphea.9,10 There
have even been reports of Sweet syndrome directly
caused by radiation therapy.11,12 It is important to
recognize that radiation can cause direct inﬂammatory
changes at the site of treatment, a pertinent consideration
in patients with existing autoimmune skin conditions.
Many radiation oncologists are hesitant to treat patients
with scleroderma or systemic lupus erythematosus, con-
ditions associated with a dysregulated immune system
that have characteristic skin ﬁndings.13 Given that reports
of patients with Sweet syndrome requiring radiation
therapy are sparse and the pathogenesis of the disease is
autoimmune, it is logical to question the safety of radia-
tion therapy in these cases as well. The initial regression
of Sweet syndrome during and after radiation therapy, as
well as the lack of signiﬁcant radiation-induced toxicity in
our patient, provides some reassurance for Sweet syn-
drome patients needing radiation therapy for the man-
agement of their malignancies.References
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